Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).

被引：1
|
作者：
Lee, Chung-Han
Shah, Amishi Yogesh
Hsieh, James J.
Rao, Arpit
Pinto, Alvaro
Bilen, Mehmet Asim
Cohn, Allen Lee
Di Simone, Christopher
Shaffer, David R.
Sarrio, Regina Girones
Ribe, Sara Gunnestad
Wu, Jane
Schmidt, Emmett, V
Perini, Rodolfo F.
Kubiak, Peter
Smith, Alan D.
Motzer, Robert J.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA
[5] Hosp Univ La Paz, Madrid, Spain
[6] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[7] Rocky Mt Canc Ctr, Denver, CO USA
[8] Arizona Oncol Associates, Tucson, AZ USA
[9] New York Oncol Hematol, Albany, NY USA
[10] Hosp Univ & Politecn La FE, Med Oncol Serv, Valencia, Spain
[11] Sorlandet Hosp Kristiansand, Kristiansand, Norway
[12] Eisai Inc, Woodcliff Lake, NJ USA
[13] Merck & Co Inc, Kenilworth, NJ USA
[14] Eisai Ltd, Hatfield, Herts, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5008
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors
    Hwang, Inhwan
    Park, Inkeun
    Yoon, Shin-kyo
    Lee, Jae Lyun
    CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E122 - E133
  • [42] PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
    Franziska Erlmeier
    Arndt Hartmann
    Michael Autenrieth
    Max Wiedemann
    Philipp Ivanyi
    Sandra Steffens
    Wilko Weichert
    Medical Oncology, 2016, 33
  • [43] Immune checkpoint inhibitor (anti PD-1/PD-L1 antibody activity in dedifferentiated endometrial carcinoma.
    Ono, Ruriko
    Nakayama, Kentaro
    Itamochi, Hiroaki
    Nakamura, Kohei
    Sasamori, Hiroki
    Yamashita, Hitomi
    Ishibashi, Tomoka
    Ishikawa, Masako
    Ohnishi, Kaori
    Minamoto, Toshiko
    Iida, Kouji
    Ishikawa, Noriyoshi
    Otsuki, Yoshiro
    Kyo, Satoru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
  • [45] Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial
    Shitara, K.
    Golan, T.
    Mileham, K.
    Voskoboynik, M.
    Rha, S.
    Gutierrez, M.
    Perets, R.
    Taylor, S.
    Chen, D.
    Keenan, T.
    Rajasagi, M.
    Healy, J.
    Shoji, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S240 - S240
  • [46] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [47] Differential expressions of PD-1, PD-L1, and PD-L2 between the primary and metastatic sites in renal cell carcinoma.
    Zhang, Xingming
    Shen, Pengfei
    Zeng, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [48] PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review
    Jang, Albert
    Sweeney, Patrick L.
    Barata, Pedro C.
    Koshkin, Vadim S.
    KIDNEY CANCER, 2021, 5 (01) : 31 - 46
  • [49] The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors
    Nuvola, Giacomo
    Mollica, Veronica
    Massari, Francesco
    Suarez, Cristina
    IMMUNOTHERAPY, 2023, 15 (17)
  • [50] Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
    Pignon, Jean-Christophe
    Jegede, Opeyemi
    Shukla, Sachet A.
    Braun, David A.
    Horak, Christine
    Wind-Rotolo, Megan
    Ishii, Yuko
    Catalano, Paul J.
    Freeman, Gordon J.
    Jennings, Rebecca B.
    De Cubas, Aguirre
    Rathmell, Kimryn
    Choueiri, Toni K.
    Atkins, Michael B.
    McDermott, David F.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345